US 11,925,626 B2
Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
Ian Scott, Dublin, CA (US); Travis Lemons, Palo Alto, CA (US); and Yip-Fong Chia, Sunnyvale, CA (US)
Assigned to Corcept Therapeutics Incorporated, Menlo Park, CA (US)
Filed by Corcept Therapeutics Incorporated, Menlo Park, CA (US)
Filed on Sep. 22, 2022, as Appl. No. 17/950,902.
Application 17/950,902 is a continuation of application No. 16/719,644, filed on Dec. 18, 2019, granted, now 11,464,764.
Claims priority of provisional application 62/781,983, filed on Dec. 19, 2018.
Prior Publication US 2023/0032377 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/437 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 9/0053 (2013.01); A61K 9/4808 (2013.01); A61K 9/4866 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01)] 21 Claims
 
1. A formulation for oral administration of relacorilant, (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, which has the following structure:

OG Complex Work Unit Chemistry
the formulation comprising:
about 18 to 22% relacorilant;
about 56% to 64% surfactant, wherein said surfactant is lauroyl polyoxyl glyceride, and
about 18% to 22% solubilizer, wherein said solubilizer is propylene glycol monocaprylate,
wherein said percentages are weight percent.